Searched for
AD ASTRA FUND
Global drugmakers rush to boost US presence as tariff threat loomsGlobal drug companies are boosting U.S. production and stockpiling medicines. This is a response to potential tariffs on branded drugs. Com...- Serum Institute of India to manufacture Oxford Ebola vaccine backed by $8.6 million CEPI fundingSerum Institute of India will produce clinical trial doses of a new Ebola vaccine from Oxford University. This initiative is backed by fres...
- Moderna and other groups get $60 million to develop Ebola vaccineCEPI is investing around $60 million to speed up the creation of vaccines against the deadly Ebola Bundibugyo virus. This funding will supp...
- HDFC Defence Fund increase stake in HAL, Bharat Electronics & 6 other stocks in AprilHDFC Defence Fund, the sector's sole actively managed offering, significantly boosted its holdings in Hindustan Aeronautics (HAL) and Bhara...
- Chinese medicines bring relief to India’s cancer patientsIndia’s cancer treatment landscape is seeing a shift as lower-cost immunotherapy drugs developed in China and marketed through Indian partn...
- Indian fund outperforming 98% of peers bets on defense stocksA $3 billion fund at Kotak Mahindra Asset Management Co. is backing Indian defense stocks, wagering that geopolitical tensions will boost l...
- HDFC Defence Fund increase stake in HAL, Eicher Motors and 4 other stocks in MarchHDFC Defence Fund significantly boosted its holdings in Hindustan Aeronautics and Eicher Motors during March, adding thousands of shares to...
- Start SIP in defence funds, growth looking solid for next 5-10 years, says Gurmeet Chadha. Here’s whyGurmeet Chadha recommends SIPs in defence funds, citing strong 5–10 year growth prospects driven by rising global tensions, increased defen...
- HDFC Defence Fund increases stake in HAL, Solar Industries, and 4 other stocks in AprilHDFC Defence Fund, India’s only active defence-focused mutual fund, raised its stake in six companies in April, including HAL, BEML, and So...
- ETMarkets PMS Talk: We’re not fighting fund managers—we’re fighting under performance’, says Sankarsh ChandaSankarsh Chanda, CEO of Savart, discusses how the Ad Astra Fund uses AI to revolutionize fund management. By automating research and overco...
- Astra Security raises $2.7 million from Emergent Ventures, othersAstra said it plans to use the funds to enhance capabilities to uncover vulnerabilities in cloud environments. It also aims to deepen its f...
- Elon Musk's new preschool ‘Ad Astra’ set to break new ground in 2025; Here's what we knowElon Musk, known for pioneering innovations in technology and space exploration, has turned his attention to education with the launch of A...
- RDIF says early results of 'mix & match' of Sputnik Light, AstraZeneca jab found to be safeAstraZeneca COVID vaccine is the same as Covishield which is used in India and several other countries.
- Confident of getting EMA's approval in a month for Covishield: Adar Poonawalla"The EMA is absolutely correct in asking us to apply, which we have through AstraZeneca, our partners, a month ago, and that process has to...
- AstraZeneca hits snag in Covid drug developmentThe drug, made from a combination of two antibodies, failed its main goal to treat Covid-19 symptoms in exposed patients, AstraZeneca said ...
- AstraZeneca to acquire Alexion in $39 billion dealAlexion shareholders will receive $60 in cash and 2.1243 AstraZeneca American Depositary Shares per Alexion share.
- AstraZeneca must prove claim to cheapest COVID-19 vaccine: MSFThe British firm said on Monday its COVID-19 vaccine was 70% effective in pivotal trials and could be up to 90% effective, giving the world...
- AstraZeneca sells ageing beta-blocker to Recordati for $300 mlnAstraZeneca, which retains rights to the beta-blocker outside Europe, will continue to manufacture and ship product to Recordati under a su...
- Jubilant Biosys receives milestone payment from AstraZenecaEarlier this week Jubilant Biosys along with US-based Endo Pharmaceuticals received an undisclosed milestone payment for their joint progra...
- AstraZeneca Pharma NCDs get P1 ratingCRISIL has assigned ‘P1+’ rating to the short term secured fully-paid redeemable non-convertible bonus debenture issue of AstraZeneca Pharm...
Load More
